We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biosensors Enable Rapid Multiplexed Pathogen Detection

By LabMedica International staff writers
Posted on 27 Jun 2013
An electronic chip has been created that can analyze blood and other clinical samples for infectious bacteria with record-breaking speed. More...


The advanced technology can identify the pathogen in a matter of minutes, and looks for many different bacteria and drug resistance markers in parallel, allowing rapid and specific identification of infectious agents.

Biomaterial engineers and other specialists at the University of Toronto (ON, Canada) developed an integrated circuit that could detect bacteria at concentrations found in patients presenting with a urinary tract infection. The solution circuit chip (SCC) consists of 100 working electrodes (WEs) with 30 off-chip contacts. It included 20 common WEs and 5 counter/reference (CE/RE) electrode pairs, with 25 probe wells to facilitate manual probe deposition and five separate liquid channels. One key to the advance was the design of an integrated circuit that could accommodate a panel of many biomarkers.

A set of peptide nucleic acid (PNA) probes were designed, synthesized and tested, and validated for sensitivity and specificity. It is these probes that make individual sensors specific for pathogens, as they are targeted to unique sequences within the genomes of the organisms. The probe set developed covered 90% of the common urinary tract pathogens and many of the major types of drug resistance that are encountered in a clinic. The results indicate that SCCs can be used for highly multiplexed pathogen detection, and can also be used to deliver the very rapid results needed to make diagnostic information clinically available.

Ihor Boszko, MSc, MBA, Director of Business Development at the molecular diagnostics company Xagenic (Toronto, ON, Canada) said the breakthrough could have significant practical implications. “This kind of highly sensitive, enzyme-free electrochemical detection technology will have tremendous utility for clinical diagnostics. Multiplexing of in vitro diagnostic approach adds the capability of simultaneously testing for multiple viruses or bacteria that produce similar clinical symptoms. It also allows for simple and cost effective manufacturing of highly multiplexed electrochemical detectors, which will certainly have a significant impact on the availability of effective diagnostic tools.” The study was published on June 12, 2013, in the journal Nature Communications.

Related Links:

University of Toronto
Xagenic



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.